Deutsche Bank
BMRN icon

Deutsche Bank’s BioMarin Pharmaceuticals BMRN Stock Holding History

Deutsche Bank’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-594
Closed -$54K – 4912
2016
Q3 		$54K Buy
+594
New +$55.9K ﹤0.01% 4188

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Deutsche Bank's BMRN Position: Q2 2026 in Review

Deutsche Bank reduced its BioMarin Pharmaceuticals (BMRN) stake by 69% in Q2 2026, selling an estimated $15.6M and leaving 126,286 shares worth $7.23M. The position accounts for ﹤0.01% of the portfolio, ranked #1183.

Deutsche Bank first reported a position in BMRN in Q2 2013 and has held it in 53 quarters since. The position peaked at $328M in Q4 2023. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

  • Deutsche Bank held 126,286 shares of BioMarin Pharmaceuticals worth $7.23M as of Q2 2026.
  • Deutsche Bank sold 285,016 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $15.6M.
  • BioMarin Pharmaceuticals made up ﹤0.01% of Deutsche Bank's portfolio in Q2 2026, its #1183 holding.
  • Deutsche Bank first reported a position in BioMarin Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
  • Deutsche Bank's BioMarin Pharmaceuticals position peaked at $328M in Q4 2023.
  • 565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Deutsche Bank's 13F filing for Q2 2026, filed 7 Aug 2026.